ReviewClinical pharmacology : advances and applications2026
Treatment of Parkinson's Disease-Related Psychosis.
Review in Clinical pharmacology : advances and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To provide an updated, clinically oriented overview of therapeutic strategies for Parkinson's disease-related psychosis (PDP), integrating current evidence on risk factors and available pharmacological and non-pharmacological treatments. Patients and Methods: This is a narrative, non-systematic review summarizing findings from targeted searches of PubMed, Embase, and Scopus, focusing on clinical trials, observational studies, consensus guidelines, and high-quality reviews addressing the epidemiology, pathophysiology, and management of PDP. Evidence was analyzed qualitatively, with emphasis on consistency of findings, clinical applicability, and areas of ongoing uncertainty. Results: PDP affects a substantial proportion of individuals with Parkinson's disease and is associated with cognitive decline, increased caregiver burden, higher rates of institutionalization, and elevated mortality. Management begins with the identification of reversible triggers, environmental optimization, and rational adjustment of antiparkinsonian medications. When antipsychotic therapy is required, pimavanserin and clozapine demonstrate the strongest evidence for efficacy. However, pimavanserin availability remains limited and long-term data are scarce. Quetiapine is widely used despite inconsistent evidence from randomized trials, largely due to its favorable safety profile and ease of use. Acetylcholinesterase inhibitors may provide benefit in selected patients, particularly those with concomitant cognitive impairment. Conclusion: Current therapeutic strategies allow symptom control in many patients, yet important gaps in the evidence base persist, particularly regarding long-term outcomes. Future research should prioritize mechanistically informed therapies, standardized outcome measures, and the identification of predictors of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.